196 related articles for article (PubMed ID: 21515735)
1. Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a.
Brennan RC; Federico S; Bradley C; Zhang J; Flores-Otero J; Wilson M; Stewart C; Zhu F; Guy K; Dyer MA
Cancer Res; 2011 Jun; 71(12):4205-13. PubMed ID: 21515735
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells.
Elison JR; Cobrinik D; Claros N; Abramson DH; Lee TC
Arch Ophthalmol; 2006 Sep; 124(9):1269-75. PubMed ID: 16966622
[TBL] [Abstract][Full Text] [Related]
3. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
[TBL] [Abstract][Full Text] [Related]
4. Targeting MDM2 and MDMX in retinoblastoma.
Laurie NA; Shih CS; Dyer MA
Curr Cancer Drug Targets; 2007 Nov; 7(7):689-95. PubMed ID: 18045074
[TBL] [Abstract][Full Text] [Related]
5. Targeted nutlin-3a loaded nanoparticles inhibiting p53-MDM2 interaction: novel strategy for breast cancer therapy.
Das M; Dilnawaz F; Sahoo SK
Nanomedicine (Lond); 2011 Apr; 6(3):489-507. PubMed ID: 21542687
[TBL] [Abstract][Full Text] [Related]
6. Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.
Pritchard EM; Dyer MA; Guy RK
Mini Rev Med Chem; 2016; 16(6):430-54. PubMed ID: 26202204
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.
Tonsing-Carter E; Bailey BJ; Saadatzadeh MR; Ding J; Wang H; Sinn AL; Peterman KM; Spragins TK; Silver JM; Sprouse AA; Georgiadis TM; Gunter TZ; Long EC; Minto RE; Marchal CC; Batuello CN; Safa AR; Hanenberg H; Territo PR; Sandusky GE; Mayo LD; Eischen CM; Shannon HE; Pollok KE
Mol Cancer Ther; 2015 Dec; 14(12):2850-63. PubMed ID: 26494859
[TBL] [Abstract][Full Text] [Related]
8. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
Michaelis M; Rothweiler F; Klassert D; von Deimling A; Weber K; Fehse B; Kammerer B; Doerr HW; Cinatl J
Cancer Res; 2009 Jan; 69(2):416-21. PubMed ID: 19147553
[TBL] [Abstract][Full Text] [Related]
9. Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.
Zhang F; Tagen M; Throm S; Mallari J; Miller L; Guy RK; Dyer MA; Williams RT; Roussel MF; Nemeth K; Zhu F; Zhang J; Lu M; Panetta JC; Boulos N; Stewart CF
Drug Metab Dispos; 2011 Jan; 39(1):15-21. PubMed ID: 20947617
[TBL] [Abstract][Full Text] [Related]
10. Nutlin sensitizes lung carcinoma cells to interferon-alpha treatment in MDM2-dependent but p53-independent manner.
Shuvalov O; Kizenko A; Shakirova A; Fedorova O; Petukhov A; Aksenov N; Vasileva E; Daks A; Barlev N
Biochem Biophys Res Commun; 2018 Jan; 495(1):1233-1239. PubMed ID: 29175211
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
12. Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma.
Nemeth KM; Federico S; Carcaboso AM; Shen Y; Schaiquevich P; Zhang J; Egorin M; Stewart C; Dyer MA
Cancer; 2011 Jan; 117(2):421-34. PubMed ID: 20818652
[TBL] [Abstract][Full Text] [Related]
13. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
[TBL] [Abstract][Full Text] [Related]
14. MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells.
Wang B; Fang L; Zhao H; Xiang T; Wang D
Acta Biochim Biophys Sin (Shanghai); 2012 Aug; 44(8):685-91. PubMed ID: 22843172
[TBL] [Abstract][Full Text] [Related]
15. MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition.
Schneider LS; Ulrich M; Lehr T; Menche D; Müller R; von Schwarzenberg K
Mol Oncol; 2016 Aug; 10(7):1054-62. PubMed ID: 27157929
[TBL] [Abstract][Full Text] [Related]
16. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
17. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
18. [TP53 and RB tumor suppressor pathways collaborate in retinoblastoma genesis].
Ayrault O; Zindy F; Roussel MF
Med Sci (Paris); 2007 Apr; 23(4):356-8. PubMed ID: 17433223
[No Abstract] [Full Text] [Related]
19. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines.
Ohnstad HO; Paulsen EB; Noordhuis P; Berg M; Lothe RA; Vassilev LT; Myklebost O
BMC Cancer; 2011 May; 11():211:1-11. PubMed ID: 21624110
[TBL] [Abstract][Full Text] [Related]
20. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin.
Efeyan A; Ortega-Molina A; Velasco-Miguel S; Herranz D; Vassilev LT; Serrano M
Cancer Res; 2007 Aug; 67(15):7350-7. PubMed ID: 17671205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
